Bookmark and Share
Phenobarbital (CID 4763) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(27)
 
 
Inactive(650)
 
 
Inconclusive(38)
 
 
Unspecified(2025)
 
 
Top Targets:
7TM GPCR Srx(31)
 
 
 
7TM GPCR Srsx(29)
 
 
 
 
p450(26)
 
 
 
 
ABCC MRP doma..(19)
 
 
NR LBD ER(16)
 
 
 
BioAssay Types:
Literature(544)
 
 
 
 
 
Screening(269)
 
 
 
Confirmatory(261)
 
 
 
 
Summary(39)
 
 
BioActivity Types:
Potency(280)
 
 
 
 
IC50(131)
 
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 2564    Data Row: 2740   Total Pages: 55   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103165722]
IC50 2.5Inhibition of [3H]BTX-B binding to neurotoxin site 2 of sodium channel of rat cerebral cortex synaptoneurosomes [AID217794, Type: Literature]Sodium channel protein type 1 subunit alpha [gi:116447]
View
2
[SID103165722]
IC50 2.5Inhibition of [3H]BTX-B binding to neurotoxin site 2 of sodium channel of rat cerebral cortex synaptoneurosomes [AID217794, Type: Literature]Sodium channel protein type 2 subunit alpha [gi:116448]
View
3
[SID103165722]
IC50 2.5Inhibition of [3H]BTX-B binding to neurotoxin site 2 of sodium channel of rat cerebral cortex synaptoneurosomes [AID217794, Type: Literature]Sodium channel protein type 3 subunit alpha [gi:116449]
View
4
[SID48414299]
DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results [AID1189, Type: other]
View
5
[SID103165722]
Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis [AID678721, Type: Literature]
View
6
[SID103165722]
Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins [AID678713, Type: Literature]Cytochrome P450 2C9 [gi:6686268]
View
7
[SID103165722]
Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins [AID678714, Type: Literature]Cytochrome P450 2C19 [gi:60416369]
View
8
[SID103165722]
Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins [AID678716, Type: Literature]Cytochrome P450 3A4 [gi:116241312]
View
9
[SID103165722]
Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins [AID678717, Type: Literature]Cytochrome P450 3A4 [gi:116241312]
View
10
[SID103165722]
Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins [AID678715, Type: Literature]Cytochrome P450 2D6 [gi:84028191]
View
11
[SID51087546]
qHTS of D3 Dopamine Receptor Antagonist: qHTS [AID652054, Type: screening]D(3) dopamine receptor isoform e [Homo sapiens] [gi:89191863]
View
12
[SID103165722]
Mouse behavior activity was determined; D = Depressant [AID134938, Type: Literature]
View
13
[SID11109645]
NINDS Anticonvulsant Data (Qualitative) [AID423, Type: other]
View
14
[SID11109645]
NINDS Anticonvulsant Data (Quantitative) [AID424, Type: other]
View
15
[SID103165722]
Anticonvulsant activity against maximal-electroshock-induced seizure in mouse at 100 mg/kg, ip after 0.5 hrs [AID290720, Type: Literature]
View
16
[SID103165722]
Anticonvulsant activity against subcutaneous pentylenetetrazole-induced seizure in mouse at 30 mg/kg, ip after 0.5 hrs [AID290723, Type: Literature]
View
17
[SID103165722]
Anticonvulsant activity against subcutaneous picrotoxin-induced seizure in mouse at 30 mg/kg, ip after 0.5 hrs [AID290725, Type: Literature]
View
18
[SID103165722]
Anticonvulsant activity against subcutaneous picrotoxin-induced seizure in mouse at 100 mg/kg, ip after 4 hrs [AID290729, Type: Literature]
View
19
[SID103165722]
Acute neurotoxicity in mouse at 100 mg/kg, ip after 0.5 hrs by rotarod test [AID290732, Type: Literature]
View
20
[SID103165722]
Acute neurotoxicity in mouse at 300 mg/kg, ip after 4 hrs by rotarod test [AID290733, Type: Literature]
View
21
[SID48414897]
DSSTox (EPAFHM) EPA Fathead Minnow Acute Toxicity [AID1188, Type: other]
View
22
[SID48416415]
DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
23
[SID51087546]
Aqueous Solubility from MLSMR Stock Solutions [AID1996, Type: other]
View
24
[SID48414299]
DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity [AID1194, Type: other]
View
25
[SID48414299]
DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results [AID1199, Type: other]
View
26
[SID48414299]
DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results [AID1205, Type: other]
View
27
[SID103165722]
Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins [AID678712, Type: Literature]Cytochrome P450 1A2 [gi:117144]
View
28
[SID103165722]
IC50 10Inhibition of [3H]BTX binding to guinea pig voltage-dependent sodium channel [AID71428, Type: Literature]
View
29
[SID103165722]
IC50 3000Inhibitory concentration against IKr potassium channel [AID240820, Type: Literature]
View
30
[SID103165722]
IC50 3019.95Inhibition of human ERG [AID576612, Type: Literature]Potassium voltage-gated channel subfamily H member 2 [gi:7531135]
View
31
[SID103165722]
IC50 3019.95Inhibition of human ERG channel in HEK293 cells by voltage-clamp method [AID392051, Type: Literature]Potassium voltage-gated channel subfamily H member 2 [gi:7531135]
View
32
[SID103165722]
IC50 DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole) [AID625171, Type: other]Potassium voltage-gated channel subfamily H member 2 [gi:7531135]
View
33
[SID103165722]
Clinically relevant inducers of human liver microsomal P450 enzymes, isoform CYP2C9 [AID589053, Type: other]Cytochrome P450 2C9 [gi:6686268]
View
34
[SID103165722]
IC50 DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) [AID625248, Type: other]Cytochrome P450 2C9 [gi:6686268]
View
35
[SID103165722]
IC50 DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4) [AID625145, Type: other]Cysteinyl leukotriene receptor 1 [gi:20138087]
View
36
[SID103165722]
IC50 DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) [AID625154, Type: other]Muscarinic acetylcholine receptor M4 [gi:23503039]
View
37
[SID103165722]
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting [AID699540, Type: Literature]Solute carrier organic anion transporter family member 1B3 [gi:27734563]
View
38
[SID103165722]
DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP) [AID625188, Type: other]Receptor-type tyrosine-protein phosphatase C [gi:33112650]
View
39
[SID103165722]
IC50 DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol) [AID625204, Type: other]Beta-1 adrenergic receptor [gi:48429211]
View
40
[SID103165722]
Constitutive androstane receptor indirect activator [AID589023, Type: other]Nuclear receptor subfamily 1 group I member 3 [gi:49066046]
View
41
[SID103165722]
TP_TRANSPORTER: Northern blot in vitro, primary hepatocytes [AID679484, Type: other]Bile salt export pump [gi:12585136]
View
42
[SID103165722]
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting [AID699539, Type: Literature]Solute carrier organic anion transporter family member 1B1 [gi:12643959]
View
43
[SID103165722]
IC50 DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr)) [AID625184, Type: other]Epidermal growth factor receptor [gi:2811086]
View
44
[SID103165722]
IC50 DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG) [AID625173, Type: other]Angiotensin-converting enzyme [gi:2822103]
View
45
[SID103165722]
IC50 DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) [AID625163, Type: other]Mu-type opioid receptor [gi:2851402]
View
46
[SID103165722]
IC50 DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808) [AID625220, Type: other]5-hydroxytryptamine receptor 4 [gi:6224984]
View
47
[SID103165722]
TP_TRANSPORTER: Western in vivo SD rat, liver [AID679817, Type: other]Canalicular multispecific organic anion transporter 1 [gi:3219824]
View
48
[SID103165722]
TP_TRANSPORTER: Western blot, H4IIE rat hepatoma cells [AID679818, Type: other]Canalicular multispecific organic anion transporter 1 [gi:3219824]
View
49
[SID103165722]
TP_TRANSPORTER: Northern blot from H4IIE rat hepatoma cells [AID679820, Type: other]Canalicular multispecific organic anion transporter 1 [gi:3219824]
View
50
[SID103165722]
TP_TRANSPORTER: Northern blot in vivo SD rat, liver [AID679181, Type: other]Canalicular multispecific organic anion transporter 1 [gi:3219824]
View